Proscar v. Cardura $50 mil. BPH disease progression comparative study begins enrollment at NIDDK.
Executive Summary
PROSCAR v. CARDURA NIDDK BPH PROGRESSION TRIAL BEGINS RECRUITMENT for a comparative study of Merck's 5-alpha-reductase inhibitor Proscar (finasteride) and Pfizer's alpha1 blocker Cardura (doxazosin) alone and in combination. The study of the progression of benign prostatic hyperplasia is being conducted under the auspices of the National Institute of Diabetes & Digestive & Kidney Diseases. It was first announced at a press conference on a 1,200-patient one-year BPH study at the Department of Veterans Affairs comparing Proscar with Abbott's Hytrin (terazosin), a combination of the two or placebo. The alpha blocker Hytrin outperformed Proscar in symptom improvement ("The Pink Sheet" Aug. 28, T&G-10).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth